Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scholar Rock Holding Corporation (SRRK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Scholar Rock files reports and current updates with the U.S. Securities and Exchange Commission (SEC) that describe its financial condition, clinical and regulatory milestones, capital markets activity, and material corporate events.
For SRRK, Form 8-K current reports are particularly important. Recent 8-K filings have covered quarterly financial and operating results, conference call presentations, and key regulatory developments such as the U.S. Food and Drug Administration’s Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) in spinal muscular atrophy (SMA). Other 8-Ks describe the inspection status of a third-party fill-finish facility, the use of an at-the-market equity offering program with Jefferies LLC, and the filing of a prospectus supplement for additional common stock issuance.
Scholar Rock’s filings also document its status as a registrant on The Nasdaq Global Select Market under the ticker SRRK, the terms of its common stock, and its use of a shelf registration statement on Form S-3ASR. Inducement equity awards granted under the company’s 2022 Inducement Equity Plan are reflected in press releases that may be furnished as exhibits to 8-Ks, providing detail on stock options and restricted stock units granted to new employees.
On Stock Titan, users can review these SEC documents alongside AI-powered summaries that explain the main points of each filing in accessible language. Real-time updates from EDGAR help surface new 8-Ks, 10-Q quarterly reports, 10-K annual reports, and any future registration statements or prospectus supplements related to Scholar Rock’s capital-raising activities. For investors analyzing SRRK’s SMA and broader neuromuscular disease programs, these filings offer primary-source insight into clinical progress, regulatory interactions, financing plans, and overall corporate strategy.
Scholar Rock Holding Corp’s Chief Scientific Officer Mo Qatanani reported an open-market sale of 7,989 shares of common stock at an average price of $46.5282 per share.
According to the footnotes, this was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from restricted stock units (RSUs) that vested on February 15, 2026, under the company’s equity incentive plans, and was not a discretionary trade. After this transaction, Qatanani’s reported holdings consist of 8,484 shares of common stock and 98,445 RSUs, which together total 106,929 units of equity-related interests.
Vaishnaw Akshay reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp reported that President of R&D and director Akshay Vaishnaw received a grant of 47,021 restricted stock units (RSUs) of common stock on February 9, 2026, at a stated price of $0.00 per share as a compensatory award.
Each RSU represents one share of common stock upon vesting and vests in four equal annual installments over four years, starting on January 15, 2027, contingent on continued service. After this grant, Vaishnaw directly holds 642,788 equity interests, consisting of 45,767 shares of common stock, 147,021 time-based RSUs, and 450,000 performance- and time-based RSUs.
Sinha Vikas reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp’s Chief Financial Officer Vikas Sinha received a grant of 47,021 restricted stock units on February 9, 2026 at a stated price of $0.00 per unit. These RSUs vest in four equal annual installments starting on January 15, 2027, as long as he remains in service. After this grant, he beneficially owns 630,266 equity-linked interests, consisting of 33,245 shares of common stock, 147,021 time-based RSUs, and 450,000 performance- and time-based RSUs.
Scholar Rock Holding Corp's Chief Scientific Officer, Mo Qatanani, reported an equity compensation award in the form of restricted stock units. On February 9, 2026, Qatanani acquired 29,258 RSUs at a stated price of $0.00 per share as a grant or award.
Each RSU represents the right to receive one share of common stock upon vesting. The 29,258 RSUs vest in four equal annual installments over four years, with the first installment scheduled to vest on January 15, 2027, and additional installments vesting annually thereafter, contingent on continued service with the company.
Following this award, Qatanani beneficially owns 114,918 RSUs directly, reflecting total time-based equity incentives tied to ongoing service with Scholar Rock.
Parlavecchio Caryn reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp’s Chief Human Resources Officer, Caryn Parlavecchio, received a grant of 29,258 restricted stock units (RSUs) of common stock on February 9, 2026 at a price of $0.00 per share.
The RSUs vest in four equal annual installments, with the first installment vesting on January 15, 2027 and the remaining installments vesting annually thereafter, contingent on continued service. Following this award, Parlavecchio directly holds 178,122 common-stock-related interests, consisting of 78,283 shares of common stock and 99,839 RSUs.
Marantz Jing L. reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp’s Chief Medical Officer, Jing L. Marantz, received a grant of 34,482 restricted stock units (RSUs) of common stock on February 9, 2026. The award was reported at a price of $0.00 per share as a compensation grant.
Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments over four years, with the first installment scheduled for January 15, 2027, as long as Dr. Marantz continues a service relationship with the company on each vesting date. After this grant, she directly holds 130,169 common shares and RSUs in total, consisting of 24,974 common shares and 105,195 RSUs.
Ho Junlin reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp’s general counsel, Junlin Ho, received a grant of 36,572 shares of common stock in the form of restricted stock units. These RSUs vest in four annual installments, starting on January 15, 2027, as long as Ho remains in service with the company.
After this award, Ho directly beneficially owns 251,125 units in total, consisting of 121,471 shares of common stock and 129,654 RSUs, aligning compensation with the long-term performance of Scholar Rock’s stock.
Hallal David reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp reported that Chief Executive Officer and director David Hallal received a grant of 128,004 restricted stock units (RSUs) of common stock on February 9, 2026 at a price of $0.00 per share. These RSUs vest in four annual installments, starting on January 15, 2027, subject to his continued service.
Following this award, Hallal beneficially owns 1,669,649 shares of common stock directly, consisting of shares and both time-based and performance-based RSUs. In addition, 205,000 shares are held indirectly by the Hallal Family Irrevocable Trust, where his spouse is a trustee and he disclaims beneficial ownership beyond his pecuniary interest.
Woods Keith reported acquisition or exercise transactions in this Form 4 filing.
Scholar Rock Holding Corp’s Chief Operating Officer Keith Woods was awarded 47,021 shares of common stock in the form of restricted stock units on February 9, 2026 at a grant price of $0.00. These RSUs vest in four equal annual installments starting January 15, 2027, as long as he remains in service.
After this award, Woods beneficially owns 630,275 equity interests, consisting of 33,254 shares of common stock, 147,021 time-based RSUs, and 450,000 RSUs subject to both performance and time-based vesting conditions.
Wellington Management Group and affiliated entities filed a Schedule 13G reporting a passive ownership stake in Scholar Rock Holding Corporation common stock. They report beneficial ownership of 5,759,428 shares, representing 5.65% of the outstanding common stock as of 12/31/2025.
The Wellington entities report no sole voting or dispositive power, but significant shared voting and dispositive power across the group, with Wellington Management Company LLP holding shared voting power over 4,973,254 shares. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Scholar Rock.